Interim Financial Statements: On August 28, 2025, ICON plc released its unaudited interim financial results for the period from January 1 to August 7, providing insights into its financial and operational performance amidst a changing healthcare environment.
Operational Efficiency: The report emphasizes ICON's capability to manage outsourced clinical research services, although it highlights ongoing risks such as trial cancellations and delays that could impact short-term revenue.
Investment Outlook
Revenue and Earnings Projections: ICON is projected to achieve $8.8 billion in revenue and $990.9 million in earnings by 2028, necessitating a 2.8% annual revenue growth and an increase in earnings of $196.7 million from the current $794.2 million.
Fair Value Estimates: The fair value of ICON's stock is estimated at $216.80, indicating a potential 22% upside from its current price. Estimates from the Simply Wall St Community range from $163.85 to $282.34, reflecting diverse investor perspectives.
Risks and Considerations
Clinical Trial Cancellations: The article notes that elevated cancellations of clinical trials could pose significant risks to revenue consistency, particularly highlighted by the recent halt of a next-generation COVID vaccine study due to a stop work notice from BARDA.
Investor Sentiment: Investors are encouraged to consider varied outlooks on ICON's future performance, as differing opinions may lead to contrasting investment decisions.
Additional Resources
Research Tools: Simply Wall St offers a free research report on ICON, providing a visual summary of the company's financial health, which can aid investors in making informed decisions.
Investment Strategies: The article suggests that extraordinary investment returns often come from independent analysis rather than following popular trends, encouraging readers to explore their own insights into ICON's potential.
ICLR
$182.45+Infinity%1D
Analyst Views on ICLR
Wall Street analysts forecast ICLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICLR is 204.92 USD with a low forecast of 172.00 USD and a high forecast of 236.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast ICLR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ICLR is 204.92 USD with a low forecast of 172.00 USD and a high forecast of 236.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
5 Hold
0 Sell
Moderate Buy
Current: 184.370
Low
172.00
Averages
204.92
High
236.00
Current: 184.370
Low
172.00
Averages
204.92
High
236.00
BMO Capital
Sean Dodge
Market Perform
initiated
$175
2025-11-12
Reason
BMO Capital
Sean Dodge
Price Target
$175
2025-11-12
initiated
Market Perform
Reason
BMO Capital analyst Sean Dodge initiated coverage of Icon with a Market Perform rating and $175 price target. The firm's analysis suggests the company's cancellations are likely remain elevated for the next few quarters. However, it also indicates the worst is probably now behind Icon, the analyst tells investors in a research note.
Baird
NULL -> Outperform
maintain
$218 -> $220
2025-10-24
Reason
Baird
Price Target
$218 -> $220
2025-10-24
maintain
NULL -> Outperform
Reason
Baird raised the firm's price target on Icon to $220 from $218 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results.
UBS
Buy -> Buy
downgrade
$240 -> $220
2025-10-24
Reason
UBS
Price Target
$240 -> $220
2025-10-24
downgrade
Buy -> Buy
Reason
UBS lowered the firm's price target on Icon to $220 from $240 and keeps a Buy rating on the shares.
TD Cowen
Charles Rhyee
Hold
downgrade
$183 -> $172
2025-10-24
Reason
TD Cowen
Charles Rhyee
Price Target
$183 -> $172
2025-10-24
downgrade
Hold
Reason
TD Cowen analyst Charles Rhyee lowered the firm's price target on Icon to $172 from $183 and keeps a Hold rating on the shares. The firm came away from the conference call still concerned on 2026 estimates, with management expecting margin pressure from pass-throughs to continue into 4Q and next year. Margin pressure from pricing is another headwind to 2026 that hasn't been felt yet.
About ICLR
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
